Immunotherapy study yields unexpectedly strong results for lung cancer patients


Researchers in Chicago presented new data Monday that has big implications for lung cancer patients. A clinical trial discovered that pairing immunotherapy drugs with standard chemotherapy could significantly increase survival rates in lung cancer patients, Stat reports.
A trial study called Keynote-189 found that newly diagnosed lung cancer patients were 51 percent more likely to be alive in a year if they underwent a regimen that combined Keytruda, an immunotherapy drug by the pharmaceutical company Merck, with standard chemotherapy, than if they received chemotherapy treatment alone. Patients with the combined treatment were also 48 percent less likely to have their cancer progress in that year.
The data from Merck's trial was presented Monday at the American Association for Cancer Research conference in Chicago. The results "eclipsed doctors' expectations," Stat noted. One oncologist told Stat that the results were "practice-changing."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Read more at Stat.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Kimberly Alters is the news editor at TheWeek.com. She is a graduate of the Medill School of Journalism at Northwestern University.
-
Why Turkey's Kurdish insurgents are laying down their arms
Under the Radar The PKK said its aims can now be 'resolved through democratic politics'
-
Book reviews: 'Girl on Girl: How Pop Culture Turned a Generation of Women Against Themselves' and 'Notes to John'
Feature The aughts' toxic pop culture and Joan Didion's most private pages
-
The FDA plans to embrace AI agencywide
In the Spotlight Rumors are swirling about a bespoke AI chatbot being developed for the FDA by OpenAI
-
Nobody seems surprised Wagner's Prigozhin died under suspicious circumstances
Speed Read
-
Western mountain climbers allegedly left Pakistani porter to die on K2
Speed Read
-
'Circular saw blades' divide controversial Rio Grande buoys installed by Texas governor
Speed Read
-
Los Angeles city workers stage 1-day walkout over labor conditions
Speed Read
-
Mega Millions jackpot climbs to an estimated $1.55 billion
Speed Read
-
Bangladesh dealing with worst dengue fever outbreak on record
Speed Read
-
Glacial outburst flooding in Juneau destroys homes
Speed Read
-
Scotland seeking 'monster hunters' to search for fabled Loch Ness creature
Speed Read